The plastic surgeon's guide to drugs affecting hemostasis

Annals of Plastic Surgery

Volumn 54, Issue 5, 2005, Pages 570-576

  Muskett, Alan ^a   Barber V, W Henry ^a   Lineaweaver, William C ^a  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

Author keywords

Anticoagulants; Hemostasis; Platelet inhibitors; Postoperative bleeding

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ANTIVITAMIN K; CELECOXIB; CILOSTAZOL; CLOPIDOGREL; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; DICOUMAROL; DIFLUNISAL; DIPYRIDAMOLE; ENOXAPARIN; ETODOLAC; HEPARIN; IBUPROFEN; INDOMETACIN; KETOROLAC; LOW MOLECULAR WEIGHT HEPARIN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; ROFECOXIB; SULINDAC; VALDECOXIB; WARFARIN;

ADULT; AGED; AGING; BLEEDING DISORDER; CARDIOTOXICITY; CLINICAL ARTICLE; ESTHETIC SURGERY; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEMATOMA; HEMOSTASIS; HIGH RISK POPULATION; HUMAN; INTESTINE ULCER; KIDNEY DYSFUNCTION; MALE; PERIOPERATIVE PERIOD; PLASTIC SURGERY; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; THROMBOEMBOLISM;

ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; FEMALE; HEMOSTASIS; HUMANS; MALE; MEDICAL HISTORY TAKING; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; POSTOPERATIVE HEMORRHAGE; RECONSTRUCTIVE SURGICAL PROCEDURES; RISK ASSESSMENT; SURGERY, PLASTIC; WARFARIN;

EID: 17744391405     PISSN: 01487043     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.sap.0000157893.66050.98     Document Type: Review

References (106)

1. Spandorfer J. The management of anticoagulation before and after procedures. Med Clin North Am. 2001;85:1109-1116.
2. Kearon C, Hirsh J. Management of anticoagulation before and after elective surgery. N Engl J Med. 1997;336:1506-1511.
3. Jafri SM. Periprocedural thromboprophylaxis in patients receiving chronic anticoagulation therapy. Am Heart J. 2004;147:3-15.
4. Fuster V, Ryden L, Asinger R, et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary: a Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society to Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the North American Society of Pacing and Electrophysiology. J Am Coll Cardiol. 2001;38:1231-1266.
5. Erkan D, Leibowitz E, Berman J, et al. Perioperative medical management of antiphospholipid syndrome: hospital for special surgery experience, review of literature, and recommendations. J Rheumatol. 2002;29:843-849.
6. Baudet EM, Oca CC, Roques XF, et al. A 5 1/2 year experience with the St. Jude medical cardiac valve prosthesis: early and late results of 737 valve replacements in 671 patients. J Thorac Cardiovasc Surg. 1985; 90:137-144.
7. Cannegieter SC, Rosendaal FR, Briet E. Thromboembolic and bleeding complications in patients with mechanical heart valve prostheses. Circulation. 1994;89:635-641.
8. Hirsh J. Duration of anticoagulant therapy after first episode of venous thrombosis in patients with inherited thrombophilia. Arch Intern Med. 1997;157:2174-2177.
9. Risk factors associated with stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials. Arch Intern Med. 1994;154:1448-1457.
10. Hambleton J, O'Reilly RA. Drugs used in disorders of coagulation. In: Katzung BG, ed. Basic and Clinical Pharmacology. 8th ed. New York, NY: Lange Medical Books/McGraw Hill; 2001:564-580.
11. Travis S, Wray R, Harrison K. Perioperative anticoagulant control. Br J Surg. 1989;76:1107-1108.
12. Kargi E, Babuccu O, Hosnuter M, et al. Complications of minor surgery in patients under anticoagulant treatment. Aesth Plast Surg. 2002;26:483-485.
13. Barlett GR. Does aspirin affect the outcome of minor cutaneous surgery? Br J Plast Surg. 1999;52:214-216.
14. Lawrence C, Sakuntabhai A, Tilling-Grosse S. Effect of aspirin and nonsteroidal antiinflammatory drug therapy on bleeding complications in dermatologic surgical patients. J Am Acad Dermatol. 1994;31: 988-992.
15. Weibert RT. Oral anticoagulant therapy in patients undergoing dental surgery. Clin Pharm. 1992;11:857-864.
16. McCormack P, Simcock PR, Tullo AB. Management of the anticoagulated patient for ophthalmic surgery. Eye. 1993;7:749-750.
17. Gainey SP, Robertson DM, Fay W, et al. Ocular surgery on patients receiving long-term warfarin therapy. Am J Ophthalmol. 1989;108: 142-146.
18. McMahan LB. Anticoagulants and cataract surgery. J Cataract Refract Surg. 1988;14:569-571.
19. Moll AC, Van Rij G. Anticoagulant therapy and cataract surgery. Doc Ophthalmol. 1989;72:367-373.
20. Robinson GA, Nylander A. Warfarin and cataract extraction. Br J Ophthalmol. 1989;73:702-703.
21. Parr NJ, Loh CS, Desmond AD. Transurethral resection of the prostate and bladder tumor without withdrawal of warfarin therapy. Br J Urol. 1989;64:623-625.
22. Lanzat M, Danna AT, Jacobson DS. New protocols for perioperative management of podiatric patients taking oral anticoagulants. J Foot Ankle Surg. 1994;33:16-19.
23. Bolton D, Costello A. Management of benign prostatic hyperplasia by transurethral laser ablation in patients treated with warfarin anticoagulation. J Urol. 1994;151:79-81.
24. Webster K, Wilde J. Management of anticoagulation in patients with prosthetic heart valves undergoing oral and maxillofacial operations. Br J Oral Maxillofac Surg. 2000;38:124-126.
25. Alam M, Goldberg LH. Serious adverse events associated with perioperative interruption of antiplatelet and anticoagulative therapy. Dermatol Surg. 2002;28:992-998.
26. Otley CC, Fewkes JL, Frank SM, et al. Complications of cutaneous surgery in patients who are taking warfarin, aspirin, on nonsteroidal anti-inflamatory drugs. Arch Dermatol. 1996;132:161-166.
27. Billingsley EM, Maloney ME. Intraoperative and postoperative bleeding problems in patients taking warfarin, aspirin, and nonsteroidal anti-inflamatory agents: a prospective study. Dermatol Surg. 1997;23: 381-385.
28. Alcalay J. Cutaneous surgery in patients receiving warfarin therapy. Dermatol Surg. 2001;27:756-829.
29. Schanbacher CF, Bennett RG. Postoperative stroke after stopping warfarin for cutaneous surgery. Dermatol Surg. 2000;26:785-789.
30. Schanbacher CF, Bennett RG. Regarding postoperative stroke after warfarin for cutaneous surgery [letter]. Dermatol Surg. 2001;27:91-92.
31. Kadayifci A, Haznedaroglu I, Savas M. Risk of withdrawing chronic anticoagulation without antithrombotic prophylaxis. Am J Gastroenterol. 1997;92:361-362.
32. White R, Mckittrick T, Hutchinson R, et al. Temporary discontinuation of warfarin therapy: changes in the international normalized ratio. Ann Intern Med. 1995;122:40-42.
33. Madura JA, Rookstool M, Wease G. The management of patients on chronic Coumadin therapy undergoing subsequent surgical procedures. Am Surg. 1994;60:542-547.
34. Katholi R, Nolan S, McGuire L. The management of anticoagulation during noncardiac operations in patients with prosthetic heart valves: a prospective study. Am Heart J. 1978;96:163-165.
35. Douketis J, Crowther M, Cherian S, et al. Physician preferences for perioperative anticoagulation in patients with a mechanical heart valve who are undergoing elective noncardiac surgery. Chest. 1999;116: 1240-1246.
36. Eckman M, Beshansky J, Durand-Zaleski I, et al. Anticoagulation for noncardiac procedures in patients with prosthetic heart valves: does low risk mean high cost? JAMA. 1990;263:1513-1521.
37. Spandorfer J, Lynch S, Weitz H, et al. Use of enoxaparin for the chronically anticoagulated patient before and after procedures. Am J Cardiol. 1999;84:478-480.
38. Galla J, Fuhs B. Outpatient anticoagulation protocol for mechanical valve recipients undergoing non-cardiac surgery. J Am Coll Cardiol 2000;135(2 suppl A):531A.
39. Ferreira I, Dos L, Tornos P, et al. Experience with enoxaparin in patients with mechanical heart valves who must withhold acenocoumarol. Heart. 2003;89:527-530.
40. Tinmouth A, Morrow B, Cruickshank M, et al. Dalteparin as periprocedure anticoagulation for patients on warfarin and at high risk of thrombosis. Ann Pharmacother. 2001;35:669-674.
41. Wilson S, Morgan J, Gray L. A model for perioperative outpatient management of anticoagulation in high-risk patients: an evaluation of effectiveness and safety. Can J Hosp Pharm. 2001;54:269-277.
42. Turpie A, Johnson J. Temporary discontinuation of oral anticoagulants: role of low molecular weight heparin (dalteparin). Can J Cardiol 2000;16(suppl F):149F.
43. Johnson J, Turpie A. Temporary discontinuation of oral anticoagulants: role of low molecular weight heparin (abstract). Thromb Haemost. 2001;P2323.
44. Heit J. Perioperative management of the chronically anticoagulated patient. J Thromb Thrombol. 2001;12:81-87.
45. McKenna R. Abnormal coagulation in the postoperative period contributing to excessive bleeding. Med Clin North Am. 2001;85:1277-1310.
46. Hankey GJ, Eikelboom JW. Antiplatelet drugs. Medical J Aust. 2003; 178:568-574.
47. Awtry EH, Loscalzo J. Aspirin. Circulation. 2000;101:1206-1218.
48. Colville-Nash PR, Willoughby DA. COX-1, COX-2 and articular joint disease: a role for chondroprotective agents. Biorheology. 2002;39: 171-179.
49. Lanas A. Clinical experience with cyclooxygenase-2 inhibitors. Rheumatology. 2002;41(suppl 1):16-22.
50. Tinsdale JE. Antiplatelet therapy in coronary artery disease: Review and update of efficacy studies. Am J Health Syst Pharm. 1998;55 (suppl 1):S8-S16.
51. Weksler BB, Pett Sb, Alonso D, et al. Differential inhibition by aspirin of vascular and platelet prostaglandin synthesis in atherosclerotic patients. N Engl J Med. 1983;308:800-805.
52. Clarke RJ, Mayo G, Price P, et al. Suppression of thromboxane A2 but not of systemic prostacyclin by controlled-release aspirin. N Engl J Med. 1991;325:1137-1141.
53. Bochner F, Lloyd J. Is there an optimal dose and formulation of aspirin to prevent arterial thromboembolism in man? Clin Sci. 1986;71: 625-631.
54. Taylor DW, Barnett HJ, Haynes RB, et al. Low-dose and high-dose acetylsalicylic acid for patients undergoing carotid endarterectomy: a randomised controlled trial-ASA and Carotid Endarterectomy(ACE) Trial Collaborators. Lancet. 1999;353:2179-2184.
55. Schror K. Aspirin and platelets: the antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis. Semin Thromb Hemost. 1997;23:349-356.
56. Mitchell AA, Akarasereenont P, Thiemermann C, et al. Selectivity of nonsteroidal anti-inflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci USA. 1993;90:11693-11697.
57. Grover R, Jones BM, Waterhouse N. The prevention of haematoma following rhytidectomy: a review of 1078 consecutive facelifts. Br J Plast Surg. 2001;54:481-486.
58. Barker DE. Prevention of bleeding following a rhytidectomy. Plast Reconstr Surg. 1974;54:651-653.
59. Straith RE, Raju DR, Hipps CJ. The study of hematomas in 500 consecutive facelifts. Plast Reconstr Surg. 1977;59:694-698.
60. Leist FD, Massen JK, Erich JB. A review of 324 rhytidectomies emphasizing complications and patient dissatisfaction. Plast Reconstr Surg. 1977;59:525-529.
61. Savi P, Heilmann E, Nurden P, et al. Clopidogrel: an antithrombotic drug acting on the ADP-dependent activation pathway of human platelets. Clin Appl Thromb Hemost. 1996;2:35-42.
62. Savcic M, Haurert J, Bachmann F, et al. Clopidogrel loading dose regimens: kinetic profile of pharmacodynamic responses in healthy subjects. Semin Thromb Haemost. 1999;25:15-19.
63. Helft G, Osende JI, Worthley JE, et al. Acute antithrombotic effect of clopidogrel in patients with atherosclerosis on aspirin. Arterioscler Thromb Vasc Biol. 2000;20:2316-2321.
64. Sharis PJ, Cannon CP, Loscalzo J. The antiplatelet effects of ticlopidine and clopidogrel. Ann Intern Med. 1998;129:394-405.
65. Schainfeld RM. Management of peripheral arterial disease and intermittent claudication. J Am Board Fam Pract. 2001;14:443-450.
66. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996;348:1329-1339.
67. Mehta SR, Yusuf S, Peters RJG, et al, for the Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet. 2001;358:527-533.
68. Mehta SR, Yusuf S. Clopidopgrel in Unstable angina to prevent Recurrent Events (CURE) Study Investigators. The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial programme: rationale, design and baseline characteristics including meta-analysis of the effects of thienopyridines in vascular disease. Eur Heart J. 2000; 21:2033-2041.
69. Harker LA, Boissel JP, Pilgrim AJ, et al. Comparative safety and tolerability of clopidogrel and aspirin: results from CAPRIE: CAPRIE Steering Committee and Investigators: clopidogrel versus aspirin in patients at risk of ischaemic events. Drug Saf. 1999;21: 325-335.
70. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345:494-502.
71. Schror K. The pharmacology of cilostazol. Diabetes Obes Metabol. 2002;4(suppl 2):S14-S19.
72. Jaff MR. Pharmacotherapy for peripheral arterial disease: emerging therapeutic options. Angiology. 2002;53:627-633.
73. Ikeda Y. Antiplatelet therapy using cilostazol, a specific PDE3 inhibitor. Thromb Haemost. 1999;82:435-438.
74. Liu Y, Fong M, Cone J, et al. Inhibition of adenosine uptake and augmentation of ischemia-induced increase of interstitial adenosine by cilostazol, and agent to treat intermittent claudication. J Cardiovasc Pharmacol. 2000;36:351-360.
75. Mallikaajun S, Mico BA, Forbes WP. A pharmacokinetic and pharmacodynamic study of the potential interaction between cilostazol and warfarin. Pharm Res 1997;14(suppl):S-555.
76. Tata PNV, Mallikaajun S, Bramer SL, et al. Plasma protein binding studies of warfarin and its displacement interaction with cilostazol. Pharm Res. 1997;14(suppl):S-555.
77. Otsuka Pharmaceuticals. Data on file. FDA Advisory Committee meeting dossier.
78. Tsuchikane E, Kobayashi T, Awata N. The potential of cilostazol in interventional cardiology. Curr Intervent Cardiol Rep. 2000;2:143-148.
79. Tamai Y, Takami H, Nakahata R, et al. Comparison of the effects of acetylsalicylic acid, ticlopidine and cilostazol on primary hemostasis using a quantitative bleeding time test apparatus. Haemostasis. 1999; 29:269-276.
80. Elam MB, Heckman J, Crouse JR, et al. Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication. Arterioscler Thromb Vasc Biol. 1998;18: 1942-1947.
81. Vane JR, Botting RM. New insights into the mode of action of anti-inflammatory drugs. Inflamm Res. 1995;44:1-10.
82. McKenna F. COX-2: separating the myth from reality. Scand J Rheumatol. 1999;109:19-29.
83. Slappendel R, Weber EWG, Benraad B, et al. Does ibuprofen increase perioperative blood loss during hip arthroplasty? Eur J Anaesth. 2002; 19:829-831.
84. Schafer A. Effects of nonsteroidal anti-inflammatory drugs on platelet function and systemic hemostasis. J Clin Pharmacol. 1995;35: 209-219.
85. McIntyre BA, Philp RB. Effect of ibuprofen on platelet function in normal subjects and hemophiliac patients. Clin Pharmacol Ther. 1978; 24:616-621.
86. Cryer B, Feldman M. Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs. Am J Med. 1998;104:413-421.
87. Hawkey CJ. Non-steroidal anti-inflammatory drug gastropathy: causes and treatment. Scand J Gastroenterol. 1996;31 (suppl 220):124-127.
88. Haslock I. Clinical economics review: gastrointestinal complications of non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther. 1998; 12:127-133.
89. Jackson LM, Hawkey CJ. COX-2 selective nonsteroidal anti-inflamatory drugs: do they really offer any advantages? Drugs. 2000;59:1207-1216.
90. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of non-steroidal antiinflammatory drugs. N Engl J Med. 1999;340:1888-1899.
91. Singh G, Triadafilopoulos G. Epidemiology of NSAID induced gastrointestinal complications. J Rheumatol. 1999;26(suppl 56):18-24.
92. Gibofsky A, Williams GW, McKenna F, et al. Comparing the efficacy of cyclooxygenase 2-specefic inhibitors in treating osteoarthritis: appropriate trial design considerations and results of a randomized, placebo-controlled trial. Arthritis Rheum. 2003;48:3102-3111.
93. Bensen WG, Fiechtner JJ, McMillen JI, et al. Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: a randomized, controlled trial. Mayo Clin Proc. 1999;74:1095-1105.
94. Williams GW, Ettlinger RE, Ruderman EM, et al. Treatment of osteoarthritis with once daily dosing regimen of celecoxib: a randomized, controlled trial. J Clin Rheumatol. 2000;6:65-74.
95. McKenna F, Borenstein D, Wendt H, et al. Celecoxib versus diclofenac in the management of osteoarthritis of the knee: a placebo-controlled, randomised, double-blind comparison. Scand J Rheumatol. 2001;30: 11-18.
96. Saag K, van der Heijde D, Fisher C, et al. Rofecoxib, a new cyclooxygenase 2 inhibitor, shows sustained efficacy, comparable with other nonsteroidal anti-inflammatory drugs: a 6-week and a 1-year trial in patients with osteoarthritis. Arch Fam Med. 2000;9:1124-1134.
97. Day R, Morrison B, Luza A, et al. A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs ibuprofen in patients with osteoarthritis. Arch Intern Med. 2000;160:1781-1787.
98. Truitt KE, Sperling RS, Ettinger WH Jr, et al. A multicenter, randomized, controlled trial to evaluate the safety profile, tolerability, and efficacy of rofecoxib in advanced elderly patients with osteoarthritis. Aging(Milano). 2001;13:112-121.
99. Lipsky PE, Isakson PC. Outcome of specific COX-2 inhibition in rheumatoid arthritis. J Rheumatol. 1997;24:9-14.
100. Ehrich EW. Early clinical experience with MK-966, a highly specific inhibitor of COX-2. The XIX ILAR Congress of Rheumatology, Singapore, 9 June 1997.
101. Brooks P, Emery P, Evans JF, et al. Interpreting the clinical significance of the differential inhibition of cyclooxygenase-1 and cyclooxygenase-2. Rheumatology. 1999;38:779-788.
102. Simon LS, Weaver AL, Graham DY, et al. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. JAMA. 1999;282:1921-1928.
103. Lanza FL, Rack MF, Simon TJ, et al. Specific inhibition of cyclooxygenase-2 with MK-0966 is associated with less gastroduodenal damage than either aspirin or ibuprofen. Aliment Pharmacol Ther. 1999; 13:761-767.
104. Hawkey C, Laine L, Simon T, et al. Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2000;43: 370-377.
105. Laine L, Harper S, Simon T, et al. A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2 inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Gastroenterology. 1999;117:776-783.
106. Stein P, Alpert J, Bussey H, et al. Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves. Chest. 2001; 119:220-2275.